Post-Marketing Surveillance (Special Use-results Surveillance on Long-term Use) With Sogroya® A Multi-centre, Prospective, Open Label, Single-arm, Observational, Non-interventional Post-marketing Study to Investigate the Long-term Safety and Clinical Parameters of Sogroya® Therapy in Patients With Adult Growth Hormone Deficiency (AGHD) (Only Severe Case) Under Normal Clinical Practice Conditions in Japan
Latest Information Update: 11 Apr 2025
At a glance
- Drugs Somapacitan (Primary)
- Indications Somatotropin deficiency
- Focus Adverse reactions
- Sponsors Novo Nordisk
Most Recent Events
- 02 Mar 2022 Status changed from not yet recruiting to recruiting.
- 11 Feb 2022 New trial record